Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases

Annals of the Rheumatic Diseases

Volumn 61, Issue 11, 2002, Pages 960-967

  Hallegua, D S ^a   Weisman, M H ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; DEXAMETHASONE; DIACETYLRHEIN; DOCOSAHEXAENOIC ACID; FISH OIL; GAMMA INTERFERON; GLUCOCORTICOID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10; RECOMBINANT RECEPTOR; RHEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BONE RADIOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHEMA; HUMAN; INFECTION; INJECTION SITE; LEUKOPENIA; LIBRARY; MEDICAL LITERATURE; MEDLINE; NEOPLASM; NEUTROPENIA; PRIORITY JOURNAL; PUBLICATION; REINFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN INDURATION; SYMPTOMATOLOGY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0036839416     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.61.11.960     Document Type: Review

References (64)

1. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-13.
2. Dinarello CA. Biological basis for interleukin-1 in disease. Blood 1996;87:2095-147.
3. Fox DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor. Arch Intern Med 2000;160:437-44.
4. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-57.
5. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
6. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
7. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
8. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999;354:1932-9.
9. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
10. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, Weinblatt M, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
11. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
12. Rutgeerls P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
13. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
14. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
15. Cohen S, Hurd E, Cush JJ, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment with interleukin-1 receptor antagonist in combination with methotrexate (MTX): Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
16. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 1998;16:27-55.
17. Dianarello CA. Role of interleukin-1 and tumor necrosis factor in systemic responses to infection and inflammation. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. 2nd Ed. New York: Raven Press; 1992:211-32.
18. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988;2:706-8.
19. Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, Pawelec G. Determination of cytokines in synovial fluids: Correlation with diagnosis and histomorphological characteristics of synovial fluid. Ann Rheum Dis 1992;51:731-4.
20. Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum 1995;38:642-8.
21. Chomarat P, Vannier E, Dechanet J, Rissoan MC, Banchereau J, Dinarello CA, et al. Balance of IL-1 receptor antagonist/IL-1β in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995;154:1432-9.
22. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
23. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-12.
24. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992;103:65-71.
25. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994;94:449-53.
26. Van den Berg WB, Joosten LAB, Helsen M, van de Loo FAJ. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994;95:237-43.
27. Pruitt JH, Copeland EM III, Moldawer LL. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock. Shock 1995;3:235-51.
28. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-84.
29. Ghivizzani SC, Kang R, Georgescu HI, Lechman ER, Jaffurs D, Engle JM, et al. Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 1997;159:3604-12.
30. Pearce WH, Sweis I, Yao JS, McCarthy WJ, Koch AE. Interleukin-1β and tumor necrosis factor-α release in normal and diseased human infrarenal aortas. J Vasc Surg 1992;16:784-9.
31. Griffin WST, Nicoll JAR, Grimaldi LME, Sheng JG, Mrak RE. The pervasiveness of interleukin-1 in Alzheimer pathogenesis: A role for specific polymorphisms in disease risk. Exp Gerontol 2000;35:481-7.
32. Sheng JG, Mrak RE, Griffin WST. Interleukin-1 expression in brain regions in Alzheimer's disease: Correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol 1995;21:290-301.
33. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000;47:365-8.
34. Shirakawa F, Tanaka Y, Oda S, Eto S, Yamashita U. Autocrine stimulation of interleukin 1α in the growth of adult human T-cell leukemia cells. Cancer Res 1989;49:1143-7.
35. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999;13:1117-25.
36. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 1992;89:958-67.
37. Sousa AR, Lane SJ, Nakhosteen JA, Lee TH, Poston RN. Expression of interleukin-1 beta (IL-1β) and interleukin-1 receptor antagonist (IL-1 ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med 1996;154:1061-6.
38. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265-71.
39. Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, Bartholomew LE, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 1990;33:810-20
40. Re F, Muzio M, De Rossi M, Polentarutti N, Giri JG, Mantovani A, et al. The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: Characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 1994;179:739-43.
41. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997;23:739-55.
42. Martel-Pelletier J, Mineau F, Jolicoeur F-C, Cloutier J-M, Pelletier J-P. In vitro effects of Diacerhein and Rhein on interleukin 1 and tumor necrosis factor-α systems in human osteoarticular synovium and chondrocytes. J Rheumatol 1998;25:753-62.
43. Hochberg MC, Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol 2001;15:583-93.
44. Maneiro E, Lopez-Armada MJ, Fernandez-Sueiro JL, Lema B, Galdo F, Blanco FJ. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J Rheumatol 2001;28:2692-9.
45. Browning JL, Ribolini A. Interferon blocks interleukin 1-induced prostaglandin release from human peripheral monocytes. J Immunol 1987;138:2857-63.
46. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:629-39.
47. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995;154:5492-9.
48. Preas HL 2nd, Reda D, Tropea M, Vandivier RW, Banks SM, Agosti JM, et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 1996;88:2465-72.
49. Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG, et al. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 1993;82:2985-90.
50. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
51. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
52. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25:1115-24.
53. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994;84:1342-8.
54. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
55. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
56. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
57. Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in health humans. Cytokine 1992;4:353-60.
58. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2001;30(suppl 2):17-20.
59. Cohen S, Moreland L, Cush J, Greenwalk MW, Block JA, Anakinra (recombinant interleukin-1 receptor antagonist): A large, placebo controlled efficacy trial of anakinra in patients with erosive rheumatoid arthritis disease [abstract]. Arthritis Rheum 2001;44(suppl):abstract LB-1.
60. Fleischmann R, Tesser J, Schechtman J, Modafferi D, Poulakos J. A safety trial of anakinra; recombinant interleukin-1 receptor antagonist (IL-1 ra), in a large, placebo controlled heterogeneous population of patients with rheumatoid arthritis. Arthritis Rheum 2001;44(suppl):S84.
61. Schiff M, Bulpitt K, Weaver A, Kazazi F, Joh T, Newmark R. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44(suppl):S79.
62. Kineret (Anakinra) Package Insert. Amgen Inc, 2001.
63. Clinical Review. Amgen, Biologic Licensing Application, STN 103950, anakinra for use in the treatment of rheumatoid arthritis. Prepared 9 July 9 2001.
64. Kineret (anakinra). FDA Arthritis Drugs Advisory Committee Briefing Package, Meeting Date: 16 August 2001, document date: 17 July 2001.